188 related articles for article (PubMed ID: 28028555)
1. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.
Harvey NC; Kanis JA; Odén A; Nakamura T; Shiraki M; Sugimoto T; Kuroda T; Johansson H; McCloskey EV
Osteoporos Int; 2015 Sep; 26(9):2347-53. PubMed ID: 26092062
[TBL] [Abstract][Full Text] [Related]
3. Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture.
Jeon S; Yu D; Kim S; Kim SW; Jeon I
Osteoporos Int; 2024 May; 35(5):795-804. PubMed ID: 38261013
[TBL] [Abstract][Full Text] [Related]
4. Application of an in-hospital, surgeon-led anti-osteoporotic medication algorithm in patients with hip fractures improves persistence to medication and can prevent the second fragility fracture.
Daskalakis II; Kritsotakis EI; Karantanas AH; Kontakis GM; Bastian JD; Tosounidis TH
Arch Orthop Trauma Surg; 2024 Feb; 144(2):683-692. PubMed ID: 38044337
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of teriparatide in in improving healing rates and bone-turnover markers of osteoporotic hip fracture: a meta-analysis.
Luo L; Lin J; Ma W; Fan J
J Pak Med Assoc; 2024 Apr; 74(4):741-751. PubMed ID: 38751272
[TBL] [Abstract][Full Text] [Related]
6. Forgetting the Frail: National Trends in Vitamin D Prescription After Fragility Fracture-A Large Insurance Claims Database Study.
Liu AM; Mirle V; Lee C; Hynes K; Dirschl DR; Strelzow J
J Am Acad Orthop Surg; 2024 May; 32(10):464-471. PubMed ID: 38484091
[TBL] [Abstract][Full Text] [Related]
7. Age- and dose-dependent effect of statin use on the risk of osteoporotic fracture in older adults.
Seo DH; Jeong Y; Cho Y; Kim SH; Hong S; Suh YJ; Ahn SH
Osteoporos Int; 2023 Nov; 34(11):1927-1936. PubMed ID: 37552294
[TBL] [Abstract][Full Text] [Related]
8. [Chinese expert consensus on treatment of osteoporotic fractures with teriparatide (2024 edition)].
; ;
Zhonghua Yi Xue Za Zhi; 2024 May; 104(17):1456-1465. PubMed ID: 38706051
[TBL] [Abstract][Full Text] [Related]
9. Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment.
Wozniak LA; Johnson JA; McAlister FA; Beaupre LA; Bellerose D; Rowe BH; Majumdar SR
Osteoporos Int; 2017 Jan; 28(1):219-229. PubMed ID: 27423660
[TBL] [Abstract][Full Text] [Related]
10. Should patients with exceptional longevity be treated for osteoporosis after a hip fracture?
Barceló M; Casademont J; Mascaró J; Gich I; Torres OH
Age Ageing; 2024 Jun; 53(6):. PubMed ID: 38899445
[TBL] [Abstract][Full Text] [Related]
11. [Prescription of osteoporosis drugs and secondary fracture prevention still at low levels and with large regional variation].
Modig K; Meyer A; Ek S; Sääf M; Hedström M
Lakartidningen; 2024 Jan; 121():. PubMed ID: 38343318
[TBL] [Abstract][Full Text] [Related]
12. Association of two geriatric treatment systems with anti-osteoporotic drug treatment and second hip fracture in patients with an index hip fracture: retrospective cohort study.
Rapp K; Roigk P; Becker C; Todd C; Rehm M; Rothenbacher D; Konnopka C; König HH; Friess T; Büchele G
BMC Geriatr; 2024 May; 24(1):395. PubMed ID: 38702593
[TBL] [Abstract][Full Text] [Related]
13. The significance of recent fracture location for imminent risk of hip and vertebral fractures-a nationwide cohort study on older adults in Sweden.
Lorentzon M; Litsne H; Axelsson KF
Osteoporos Int; 2024 Jun; 35(6):1077-1087. PubMed ID: 38521820
[TBL] [Abstract][Full Text] [Related]
14. Secondary fracture prevention in Spanish primary care: results of the PREFRAOS Study.
Martínez-Laguna D; Carbonell Abella C; Bastida JC; González M; Micó-Pérez RM; Vargas F; Díaz Torres E; Canals L;
Arch Osteoporos; 2024 May; 19(1):35. PubMed ID: 38722400
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic advantage of teriparatide in very elderly patients with proximal femoral fractures: a functional and BMD analysis.
Sheng OC; Wu WT; Peng CH; Yao TK; Chen IH; Wang JH; Yeh KT
BMC Musculoskelet Disord; 2024 Apr; 25(1):288. PubMed ID: 38614984
[TBL] [Abstract][Full Text] [Related]
16. The Nottingham Spinal Health (NoSH) Study: a cohort study of patients hospitalised with vertebral fragility fractures.
Ong T; Sahota O; Gladman JRF
Osteoporos Int; 2020 Feb; 31(2):363-370. PubMed ID: 31696271
[TBL] [Abstract][Full Text] [Related]
17. Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study.
Leung MTY; Turner JP; Marquina C; Ilomaki J; Tran T; Bell JS
Osteoporos Int; 2024 Apr; 35(4):669-678. PubMed ID: 38195713
[TBL] [Abstract][Full Text] [Related]
18. Anti-Osteoporosis Medication Prescriptions and Incidence of Subsequent Fracture Among Primary Hip Fracture Patients in England and Wales: An Interrupted Time-Series Analysis.
Hawley S; Leal J; Delmestri A; Prieto-Alhambra D; Arden NK; Cooper C; Javaid MK; Judge A;
J Bone Miner Res; 2016 Nov; 31(11):2008-2015. PubMed ID: 27377877
[TBL] [Abstract][Full Text] [Related]
19. Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review.
Chiu CK; Kuo MC; Yu SF; Su BY; Cheng TT
BMC Musculoskelet Disord; 2013 Sep; 14():276. PubMed ID: 24060442
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of hospitalised patients with vertebral fragility fractures: a systematic review.
Ong T; Kantachuvesiri P; Sahota O; Gladman JRF
Age Ageing; 2018 Jan; 47(1):17-25. PubMed ID: 29253103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
